Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen

British Journal of Pharmacology

Volumn 157, Issue 8, 2009, Pages 1419-1426

  Chang, Kuo Chu ^a   Liang, Jin Tung ^b   Tsai, Pei Shan ^a   Wu, Ming Shiou ^b   Hsu, Kwan Lih ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation end products; Aortic input impedance; Pulse wave reflection; Pyridoxamine; Streptozotocin diabetic rats

Indexed keywords

COLLAGEN; GLUCOSE; PYRIDOXAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; GLUCOSE BLOOD LEVEL; GLYCATION; HEART LEFT VENTRICLE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; AORTA; ARTERIES; CARDIAC OUTPUT; CARDIOMEGALY; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; PULSATILE FLOW; PYRIDOXAMINE; RATS; RATS, WISTAR;

EID: 70350341456     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00309.x     Document Type: Article

References (40)

1. Ahmed N, Thornalley PJ (2007). Advanced glycation endproducts: what is their relevance to diabetic complications. Diabetes Obes Metab 9: 233-245.
2. Amarnath V, Amarnath K, Amarnath K, Davies S, Roberts LJ Jr (2004). Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem Res Toxicol 17: 410-415.
3. Baynes JW, Thorpe SR (1999). Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9.
4. Brownlee M (2005). The pathobiology of diabetic complications. Diabetes 54: 1615-1625.
5. Brownlee M, Cerami A, Vlassara H (1988). Advanced glycosyla-tion end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321.
6. Bucala R (1997). Lipid and lipoprotein modification by GEA's: role in atherosclerosis. Exp Physiol 82: 327-337.
7. Chang KC, Hsu KL, Tseng YZ (2003). Effects of diabetes and gender on mechanical properties of the arterial system in rats: aortic impedance analysis. Exp Biol Med 228: 70-78.
8. Chang KC, Hsu KL, Tseng CD, Lin YD, Cho YL, Tseng YZ (2006). Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol 147: 944-950.
9. Cox RH (1974). Three-dimensional mechanics of arterial segments in vitro methods. J Appl Physiol 36: 381-384.
10. Crijns FR, Struijker-Boudier HA, Wolffenbuttel BH (1998). Arteriolar reactivity in conscious diabetic rats. Influence of aminoguanidine treatment. Diabetes 47: 918-923.
11. Culbertson SM, Vassilenko EI, Morrison LD, Ingold KU (2003). Paradoxical impact of antioxidants on post-amadori glycoxidation: counterintuitive increase in the yields of pentosidine and N(e)-carboxymethyllysine using a novel multifunctional pyridoxamine derivative. J Biol Chem 278: 38384-38394.
12. Degenhardt TP, Khalifah RG, Klaich GM, Schotzinger RJ (2002). Phar-macokinetics, tolerability and biologic activity of oral pyridorin™, a novel age inhibitor, in patients with type 1 diabetes and diabetic nephropathy. J Am Soc Nephrol 13: 652A.
13. Gaballa MA, Raya TE, Hoover CA, Goldman S (1999). Effects of endot-helial and inducible nitric oxide synthases inhibition on circulatory function in rats after myocardial infarction. Cardiovasc Res 42: 627-635.
14. Guyton AC (1992). Overview of the circulation; medical physics of pressure, flow, resistance, and vascular compliance. In: Wonsiewicz MJ (ed.). Human Physiology and Mechanisms of Disease. Saunders: Philadelphia, PA, p. 115.
15. Hill MA, Ege EA (1994). Active and passive mechanical properties of isolated arterioles from STZ-induced diabetic rats. Effect of ami-noguanidine treatment. Diabetes 43: 1450-1456.
16. Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P et al. (1993). Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92: 1407-1411.
17. Laxminarayan S, Sipkema P, Westerhof N (1978). Characterization of the arterial system in the time domain. IEEE Trans Biomed Eng 25: 177-184.
18. Liu A, Brin KP, Yin FCP (1986). Estimation of total arterial compliance: an improved method and evaluation of current methods. Am J Physiol 251 (Heart Circ Physiol 20): H588-H600.
19. Milnor WR (1989). Hemodynamics. Williams & Wilkins Co.: Baltimore, MD.
20. Mitchell GF, Pfeffer MA, Westerhof N, Pfeffer JM (1994). Measurement of aortic input impedance in rats. Am J Physiol 267 (Heart Circ Physiol 36): H1907-H1915.
21. Nagaraj RH, Sarkar P, Mally A, Biemel KM, Lederer MO, Padayatti PS (2002). Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 402: 110-119.
22. Nichols WW, O'Rourke MF (2005). McDonald's Blood Flow in Arteries. Arnold: London.
23. O'Rourke MF, Avolio AP, Nichols WW (1987). Left ventricular-systemic arterial coupling in humans and strategies to improve coupling in disease states. In: Yin FCP (ed.). Ventricular/Vascular Coupling.Springer-Verlag: New York, pp. 1-19.
24. Pieper GM (1999). Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 42: 204-213.
25. Pieper GM, Moore-Hilton G, Roza AM (1996). Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB rat. Life Sci 58: 147-152.
26. Singh R, Barden A, Mori T, Beilin L (2001). Advanced glycation end-products: a review. Diabetologia 44: 129-146.
27. Snyder T, Bredt A (1992). Biological roles of nitric oxide. Sci Am 5: 68-77.
28. Stadler K, Jenei V, Somogyi A, Jakus J (2005). Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats. Diabetes Metab Res Rev 21: 189-196.
29. Swaminathan S, Shah SV (2008). Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr Opin Nephrol Hy 17: 143-148.
30. Takatori A, Ishii Y, Itagaki S, Kyuwa S, Yoshikawa Y (2004). Amelioration of the beta-cell dysfunction in diabetic APA hamster by anti-oxidants and AGE inhibitor treatments. Diabetes Metab Res Rev 20: 211-218.
31. Thomas MC, Baynes JW, Thorpe SR, Cooper ME (2005). The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6: 453-474.
32. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP et al. (1993). Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42: 221-232.
33. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T (1992). Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 44: 103-150.
34. Turk Z, Mi-ur I, Turk N, Benko B (1999). Rat tissue collagen modified by advanced glycation: Correlation with duration of diabetes and glycemic control. Clin Chem Lab Med 37: 813-820.
35. Voziyan PA, Hudson BG (2005). Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 62: 1671-1681.
36. Voziyan PA, Metz TO, Baynes JW, Hudson BG (2002). A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277: 3397-3403.
37. Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Serianni AS et al. (2003). Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 278: 46616-46624.
38. Westerhof N, Sipkema P, Vanden Bos GC, Elzinga G (1972). Forward and backward waves inthe arterial system. Cardiovasc Res 6: 648-656.
39. Williams ME, Bolton WK, Degenhardt TP, Schotzinger RJ (2003). A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206). J Am Soc Nephrol 14: 7A.
40. Zatz R, Brenner BM (1986). Pathogenesis of diabetic microangiopathy: the hemodynamic view. Am J Med 80: 443-453.